UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 


 

Date of Report (Date of earliest event reported): May 10, 2018

 

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in charter)

 

DELAWARE

 

1-11083

 

04-2695240

(State or other

 

(Commission

 

(IRS employer

jurisdiction of

 

file number)

 

identification no.)

incorporation)

 

 

 

 

 

300 Boston Scientific Way, Marlborough, Massachusetts

 

01752-1234

(Address of principal executive offices)

 

(Zip code)

 

Registrant’s telephone number, including area code:   (508) 683-4000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o       Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   o

 

 

 



 

Item 5.07                                           Submission of Matters to a Vote of Security Holders.

 

(a)                                 Boston Scientific Corporation (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”) on May 10, 2018 at its Corporate Headquarters located in Marlborough, Massachusetts.

 

(b)                                 The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

 

(1)         All ten director nominees were elected to the Company’s Board of Directors for a one-year term to hold office until the Company’s 2019 Annual Meeting of Stockholders and until their successors have been elected and qualified.

 

Nominee

 

For

 

Withheld

 

Broker Non-Votes

 

Nelda J. Connors

 

1,147,969,499

 

19,080,238

 

47,343,496

 

Charles J. Dockendorff

 

1,155,396,690

 

11,653,047

 

47,343,496

 

Yoshiaki Fujimori

 

1,165,031,055

 

2,018,682

 

47,343,496

 

Donna A. James

 

1,165,745,175

 

1,304,562

 

47,343,496

 

Edward J. Ludwig

 

1,154,243,535

 

12,806,202

 

47,343,496

 

Stephen P. MacMillan

 

1,159,357,189

 

7,692,548

 

47,343,496

 

Michael F. Mahoney

 

1,139,020,766

 

28,028,971

 

47,343,496

 

David J. Roux

 

1,164,956,759

 

2,092,978

 

47,343,496

 

John E. Sununu

 

1,162,781,637

 

4,268,100

 

47,343,496

 

Ellen M. Zane

 

1,165,213,784

 

1,835,953

 

47,343,496

 

 

(2)                     The advisory vote on the compensation for the Company’s “Named Executive Officers” as disclosed in the Company’s proxy statement for the Annual Meeting was approved.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,115,591,751

 

49,959,908

 

1,498,078

 

47,343,496

 

 

(3)                     The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2018 fiscal year was ratified.

 

For

 

Against

 

Abstain

 

1,200,883,230

 

12,635,524

 

874,479

 

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

May 11, 2018

BOSTON SCIENTIFIC CORPORATION

 

 

 

 

 

By:

/s/ Vance R. Brown

 

 

Vance R. Brown

 

 

Vice President and Chief Corporate Counsel

 

3